Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Medical Genetics · Methylmalonic Acidemia with Homocystinuria, cblC Type

The Biology of B12: Why the cblC Defect Happens

At a Glance

In cblC-type MMA-HCU, mutations that disrupt the MMACHC protein prevent vitamin B12 from becoming its two active forms. As a result, methylmalonic acid and homocysteine build up while methionine falls; this lab pattern guides diagnosis alongside genetic and follow-up testing.

Understanding the biology of Methylmalonic Acidemia with Homocystinuria (MMA-HCU) requires looking inside the cell, where a complex “assembly line” processes Vitamin B12. In the most common form, the cblC defect, a specific breakdown in this processing leads to the unique biochemical signature that doctors use to raise suspicion for the diagnosis [1][2].

The Assembly Line Analogy

Think of Vitamin B12 (cobalamin) as a raw material arriving at a factory. To be useful, it must be processed and sent to two different departments:

  1. Department A (The Cytoplasm): Here, B12 is turned into methylcobalamin. This “key” helps an enzyme turn homocysteine (a byproduct of protein) into methionine (a vital building block for the body) [3].
  2. Department B (The Mitochondria): Here, B12 is turned into adenosylcobalamin. This “key” allows the body to break down certain fats and proteins. Without it, methylmalonic acid (MMA) builds up [3][4].

In the cblC defect, the “sorting machine”—the MMACHC protein—is broken. Because it fails to process the B12 at the very beginning, neither department gets the keys they need. As a result, homocysteine and MMA both back up like an overflowing line, while levels of methionine drop [1][2].

Auditing Your Lab Results

When you look at a metabolic lab report before treatment starts, three specific markers tell the story of the cblC defect. This pattern helps separate it from other conditions, though these values vary wildly based on age, treatment, diet, and lab methods. You should never use these numbers to self-diagnose or judge treatment success without your specialist.

Marker Typical Finding in cblC Why?
Total Homocysteine (tHcy) High It isn’t being converted into methionine [2][5].
Methylmalonic Acid (MMA) High (in blood and urine) It isn’t being broken down in the mitochondria [2].
Methionine Low The body cannot produce enough of this essential building block [6].

Doctors also look at C3 (propionylcarnitine) on newborn screens. C3 is a screening marker, not a definitive diagnosis. While often high, C3 can sometimes be normal in milder cases, which is why “second-tier” testing of MMA and homocysteine is critical for an accurate diagnosis [7][8].

Decoding the Genetics: The MMACHC Gene

The primary cause of this condition is a mutation in the MMACHC gene. We all have two copies of this gene (one from each parent). To have the cblC defect, both copies must have a mutation—this is called autosomal recessive inheritance [9][10].

If genetic testing finds only one mutation (or none) but the labs clearly show high MMA and homocysteine, doctors may look for rarer causes:

  • Epimutations (epi-cblC): Sometimes the gene itself is fine, but a “silencer” (caused by a nearby gene called PRDX1) turns the MMACHC gene off [11][12].
  • Other Combined Defects: Rare mutations in other genes (cblD, cblF, cblJ, or cblX) can also disrupt the B12 processing at different points [13][14].

Differentiating from Other Conditions

It is vital to distinguish the cblC defect from conditions that look similar on paper but require different treatments:

  • Isolated MMA: Only Department B is broken. MMA is high, but homocysteine is usually normal [2].
  • Isolated Homocystinuria: Only Department A is broken. Homocysteine is high, but MMA is normal [2].
  • Nutritional/Acquired B12 Deficiency: If a person (or a nursing mother) lacks B12 in their diet, both MMA and homocysteine can rise. In newborns identified through screening, maternal B12 deficiency must be distinguished from genetic disease by clinical context and follow-up assessment [15][16].

By identifying the combined pattern of high MMA, high homocysteine, and low methionine, your care team can confirm the cblC defect and start the specific treatments needed to improve intracellular processing.

Common questions in this guide

What happens to vitamin B12 in the cblC defect?
The MMACHC protein normally processes vitamin B12 into two usable forms: methylcobalamin and adenosylcobalamin. When this step is impaired, cells cannot use B12 normally, so homocysteine and methylmalonic acid build up and methionine often falls.
What lab pattern can suggest cblC-type MMA-HCU?
Before treatment, cblC-type MMA-HCU commonly shows high total homocysteine, high methylmalonic acid in blood and urine, and low methionine. C3 may also be high on a newborn screen, but results vary with age, treatment, diet, and laboratory methods and cannot confirm the diagnosis by themselves.
How is cblC-type MMA-HCU inherited?
cblC-type MMA-HCU is usually inherited in an autosomal recessive pattern, meaning a person must receive a changed copy of MMACHC from each parent. Genetic testing can help determine whether both copies contain relevant changes.
Can vitamin B12 deficiency look like cblC on lab tests?
Yes. Nutritional or acquired B12 deficiency, including deficiency in a nursing mother, can raise both methylmalonic acid and homocysteine. Doctors use clinical context, maternal B12 testing when relevant, follow-up testing, and genetic evaluation to distinguish it from cblC.
What does a C3 result mean on a newborn screen?
C3, or propionylcarnitine, is a screening marker that may be elevated in cblC-type MMA-HCU, but it is not a definitive diagnosis. C3 can be normal in milder cases, so second-tier methylmalonic acid and homocysteine testing may be needed.
How can cblC be distinguished from isolated MMA or homocystinuria?
In cblC, both methylmalonic acid and homocysteine are typically high, while methionine is often low. Isolated methylmalonic acidemia usually raises MMA without high homocysteine, whereas isolated homocystinuria raises homocysteine without high MMA.
What if genetic testing finds only one MMACHC mutation?
If laboratory findings strongly suggest cblC but testing finds one or no MMACHC mutations, clinicians may look for an epimutation involving the nearby PRDX1 gene or rare changes in other cobalamin-processing genes. A metabolic genetics team interprets these results alongside biochemical testing.

Get notified when new evidence is published on Methylmalonic acidemia with homocystinuria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Intracellular processing of vitamin B12 by MMACHC (CblC).

    Hannibal L, Jacobsen DW

    Vitamins and hormones 2022; (119()):275-298 doi:10.1016/bs.vh.2022.02.001.

    PMID: 35337623
  2. 2

    Inherited defects of cobalamin metabolism.

    Watkins D, Rosenblatt DS

    Vitamins and hormones 2022; (119()):355-376 doi:10.1016/bs.vh.2022.01.010.

    PMID: 35337626
  3. 3

    The human B12 trafficking chaperones: CblA, ATR, CblC and CblD.

    Li Z, Gouda H, Pillay S, et al.

    Methods in enzymology 2022; (668()):137-156 doi:10.1016/bs.mie.2021.12.009.

    PMID: 35589192
  4. 4

    Vitamin B12 , folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation.

    Froese DS, Fowler B, Baumgartner MR

    Journal of inherited metabolic disease 2019; (42(4)):673-685 doi:10.1002/jimd.12009.

    PMID: 30693532
  5. 5

    Neonatal-onset cblC-type methylmalonic acidemia combined with homocysteinemia: case report.

    Zhang G, Zhang L, Liu H

    Frontiers in pediatrics 2026; (14()):1878193 doi:10.3389/fped.2026.1878193.

    PMID: 42591385
  6. 6

    Pilot Study on Neonatal Screening for Methylmalonic Acidemia Caused by Defects in the Adenosylcobalamin Synthesis Pathway and Homocystinuria Caused by Defects in Homocysteine Remethylation.

    Kagawa R, Tajima G, Maeda T, et al.

    International journal of neonatal screening 2021; (7(3)) doi:10.3390/ijns7030039.

    PMID: 34287232
  7. 7

    Milder Form of Cobalamin C Disease May Be Missed by Newborn Screening: The Importance of Methylmalonic Acid Assessment.

    Nardecchia F, De Giorgi A, Santagata S, et al.

    International journal of neonatal screening 2025; (11(3)) doi:10.3390/ijns11030077.

    PMID: 40981307
  8. 8

    Cobalamin C Disease Missed by Newborn Screening in a Patient with Low Carnitine Level.

    Ahrens-Nicklas RC, Serdaroglu E, Muraresku C, Ficicioglu C

    JIMD reports 2015; (23()):71-5 doi:10.1007/8904_2015_429.

    PMID: 25772322
  9. 9

    Mutation spectrum and genotype-phenotype correlation of pediatric patients with methylmalonic acidemia.

    Lu F, Zhang B, Yang Y, et al.

    Pediatric research 2025; (98(1)):174-181 doi:10.1038/s41390-024-03687-2.

    PMID: 39501060
  10. 10

    Versatile enzymology and heterogeneous phenotypes in cobalamin complementation type C disease.

    Esser AJ, Mukherjee S, Dereven'kov IA, et al.

    iScience 2022; (25(9)):104981 doi:10.1016/j.isci.2022.104981.

    PMID: 36105582
  11. 11

    PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations.

    Cavicchi C, Oussalah A, Falliano S, et al.

    Clinical epigenetics 2021; (13(1)):137 doi:10.1186/s13148-021-01117-2.

    PMID: 34215320
  12. 12

    Late-onset epi-cblC methylmalonic aciduria with tissue-variable MMACHC promoter methylation due to a stop retained PRDX1 variant.

    Škopková M, Kabelíková P, Andrésová A, et al.

    Clinical epigenetics 2026; (18(1)).

    PMID: 42002808
  13. 13

    Prenatal diagnosis of combined methylmalonic acidemia and homocystinuria cobalamin C type using clinical exome sequencing and targeted gene analysis.

    Hwang N, Jang JH, Cho EH, et al.

    Molecular genetics & genomic medicine 2021; (9(11)):e1838 doi:10.1002/mgg3.1838.

    PMID: 34655177
  14. 14

    Novel exon-skipping variant disrupting the basic domain of HCFC1 causes intellectual disability without metabolic abnormalities in both male and female patients.

    Wongkittichote P, Wegner DJ, Shinawi MS

    Journal of human genetics 2021; (66(7)):717-724 doi:10.1038/s10038-020-00892-9.

    PMID: 33517344
  15. 15

    Implementation of second-tier tests in newborn screening for the detection of vitamin B12 related acquired and genetic disorders: results on 258,637 newborns.

    Pajares S, Arranz JA, Ormazabal A, et al.

    Orphanet journal of rare diseases 2021; (16(1)):195 doi:10.1186/s13023-021-01784-7.

    PMID: 33931066
  16. 16

    Acquired Vitamin B12 Deficiency in Newborns: Positive Impact on Newborn Health through Early Detection.

    Lipari Pinto P, Florindo C, Janeiro P, et al.

    Nutrients 2022; (14(20)) doi:10.3390/nu14204397.

    PMID: 36297083

This page explains how the cblC defect affects vitamin B12 processing and how related lab patterns support evaluation for informational purposes only and does not constitute medical advice. A metabolic specialist or genetic counselor should interpret your or your child's results.